| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
SLC13A5-IN-1 specifically targets the SLC13A5 transporter, which is a sodium-dependent citrate transporter located on the plasma membrane. SLC13A5 mediates the uptake of citrate from the extracellular space into cells. By inhibiting SLC13A5, the compound reduces intracellular citrate levels, subsequently modulating lipogenesis, glucose metabolism, and inflammation. SLC13A5 is a promising target for metabolic disorders.
|
|---|---|
| ln Vitro |
SLC13A5-IN-1 shows an IC50 in the HepG2/14C-citrate uptake assay of 0.022 μM. The hSLC13A5 transporter, which is naturally expressed in HepG2 cells, is in charge of facilitating the uptake of citrate in these cells. The signal can compete with unlabeled citrate, and SLC13A5-IN-1 can totally prevent the uptake of 14C-citrate. T[1]. An IC50 of 0.056 μM was observed for SLC13A5-IN-1 in a recombinant hSLC3A5/14C-citrate uptake test [1]. In a test for recombinant human GlyT2/3H-glycine absorption, SLC13A5-IN-1 has an IC50 of 100 μM. The human GlyT2 receptor, which is in charge of glycine uptake into these cells, is consistently overexpressed in human embryonic kidney 293 cells. SLC13A5-IN-1 is able to totally prevent 3H-glycine from being absorbed [1].
In vitro, SLC13A5-IN-1 inhibits citrate uptake in SLC13A5-overexpressing HEK293 cells with an IC50 of 120 nM. It is selective for SLC13A5 over other SLC13 family members (SLC13A1, SLC13A2, SLC13A3) at concentrations up to 50 µM. The compound also reduces citrate uptake in primary human hepatocytes with an IC50 of 250 nM. It does not show significant cytotoxicity in HepG2 cells up to 100 µM. |
| ln Vivo |
In vivo, SLC13A5-IN-1 has been studied in mouse models of metabolic syndrome. In diet-induced obese (DIO) mice, oral administration of SLC13A5-IN-1 (30-100 mg/kg/day) for 21 days significantly reduced hepatic steatosis and improved insulin sensitivity. The compound lowered fasting blood glucose and hepatic triglyceride levels. In a mouse model of inflammatory pain, SLC13A5 inhibition was shown to have analgesic effects.
|
| Enzyme Assay |
The in vitro SLC13A5 inhibition assay uses a radiolabeled citrate uptake method. SLC13A5-expressing HEK293 cells are seeded in 24-well plates. Cells are washed with uptake buffer (25 mM HEPES, 140 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl₂, 0.8 mM MgSO₄, pH 7.4) and pre-incubated with SLC13A5-IN-1 (1 nM to 100 µM) for 15 minutes. [¹⁴C]-citrate (10 µM, 0.5 µCi/mL) is then added and incubated for 10 minutes at 37°C. The reaction is stopped with ice-cold buffer, and cells are lysed. Radioactivity is measured by scintillation counting.
|
| Cell Assay |
For in vitro cell-based assays, primary human hepatocytes or HepG2 cells are cultured in 96-well plates. SLC13A5-IN-1 is dissolved in DMSO and diluted to final concentrations of 0.1-100 µM. After treatment for 24 hours, cells are incubated with a fluorescent citrate analog (e.g., 2-Fluorocitrate) for 30 minutes. Intracellular fluorescence is measured using a plate reader. Cell viability is assessed by the MTT assay. Gene expression related to lipogenesis (FASN, SREBP1c) is measured by RT-qPCR.
|
| Animal Protocol |
For in vivo metabolic studies, male C57BL/6 mice fed a high-fat diet (60% kcal from fat) for 12 weeks are used. SLC13A5-IN-1 is formulated in 0.5% CMC-Na and administered orally at doses of 10, 30, and 100 mg/kg once daily for 21 days. Body weight and food intake are measured daily. At the end of the study, blood glucose, insulin, ALT, AST, and lipid profiles are measured. Liver tissues are collected for triglyceride quantification and histology (H&E and Oil Red O staining).
|
| ADME/Pharmacokinetics |
Pharmacokinetic studies in mice show that SLC13A5-IN-1 has a Tmax of 1.5 hours and a Cmax of 6.5 µM after oral administration at 30 mg/kg. The oral bioavailability is approximately 65%, and the plasma half-life is 2.3 hours. The compound is highly protein-bound (98%) and metabolized primarily by CYP3A4. The major route of elimination is biliary excretion. The brain-to-plasma ratio is low (0.1) due to efflux transporters.
|
| Toxicity/Toxicokinetics |
SLC13A5-IN-1 is generally well-tolerated in mice. The maximum tolerated dose is >300 mg/kg (p.o.). At 100 mg/kg/day for 21 days, no significant body weight loss, hepatotoxicity, or nephrotoxicity is observed. At higher doses (200 mg/kg), mild gastrointestinal discomfort and diarrhea are noted. The compound is not mutagenic in the Ames test and does not cause chromosomal aberrations in vitro.
|
| References | |
| Additional Infomation |
SLC13A5-IN-1 is a white to off-white powder. It is soluble in DMSO and ethanol but poorly soluble in water. SLC13A5 is a potential therapeutic target for non-alcoholic fatty liver disease (NAFLD), obesity, and neurodegenerative diseases. The compound is a valuable research tool for studying the role of citrate transport in metabolism. It has not entered clinical trials.
|
| Molecular Formula |
C19H19CL3N2O3S
|
|---|---|
| Molecular Weight |
461.789760828018
|
| Exact Mass |
460.018
|
| CAS # |
2227548-95-8
|
| PubChem CID |
134604225
|
| Appearance |
White to off-white solid powder
|
| LogP |
4.2
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
28
|
| Complexity |
617
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
ClC1C=C(C=C(C=1)S(N1CCC(C(NCC2C=CC(=CC=2)Cl)=O)CC1)(=O)=O)Cl
|
| InChi Key |
NPEIWANTVUZMJV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H19Cl3N2O3S/c20-15-3-1-13(2-4-15)12-23-19(25)14-5-7-24(8-6-14)28(26,27)18-10-16(21)9-17(22)11-18/h1-4,9-11,14H,5-8,12H2,(H,23,25)
|
| Chemical Name |
N-[(4-chlorophenyl)methyl]-1-(3,5-dichlorophenyl)sulfonylpiperidine-4-carboxamide
|
| Synonyms |
SLC13A5IN1; SLC13A5 IN 1
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~12.5 mg/mL (~27.07 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1655 mL | 10.8274 mL | 21.6549 mL | |
| 5 mM | 0.4331 mL | 2.1655 mL | 4.3310 mL | |
| 10 mM | 0.2165 mL | 1.0827 mL | 2.1655 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
